Dose optimization of the central nervous system acting compound considering its altered pharmacokinetics and pharmacodynamics in patients with acute renal failure

2014 Fiscal Year Final Research Report

• Project/Area Number: 24590192
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: Okayama University
• Principal Investigator: AIBA TETSUYA 岡山大学, 医歯(薬)学総合研究科, 准教授 (00231754)
• Co-Investigator(Kenkyū-buntansha): KITAMURA Yoshihisa 岡山大学, 大学院医歯薬学総合研究科, 准教授 (40423339)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 腎不全 / PK/PD / 代謝 / 睡眠薬 / 鎮静薬 / 中枢神経系 / 投与設計

Outline of Final Research Achievements

An increased potency of the central nervous system (CNS) acting compounds are often observed in the patients with acute renal failure (ARF), even in the case of the compounds mainly undergoing the hepatic drug metabolism. Mechanisms underlying the increased potency are investigated in this study. It was revealed that the hepatic drug metabolism is suppressed with inflammation accompanying with ARF, leading to an increased plasma concentration of the compound. In addition, it was demonstrated that the suppressive neuron function is elevated with ARF. These pharmacokinetic and pharmacodynamic factors are probably involved with the ARF-related increased potency of the CNS acting compounds.

Free Research Field

臨床薬物動態学